Fig. 6
Sensitivity of COSCC to assorted drug approaches. (A–G) The determined IC50 value for each drug (A) docetaxel, (B) 5-fluorouracil, (C) cetuximab, (D) carmustine, (E) temozolomide, (F) trametinib, (G) dabrafenib) for each COSCC cell line was plotted against data from the NCI-60. For each graph, the canine cell lines are highlighted as red bars, and the y-axis crosses the x-axis at the average IC50 value across all NCI-60 cell lines. Notably, the data for carmustine included an extended set of cell lines, so more bars are present than for the other drugs. (H) Co-F-1236 or Co-O-172 cells were treated with trametinib (125 nM or 315 nM respectively) and the indicated amounts of dabrafenib (Dab: 0, 2.5, 5, or 10 µM) for 6 days, and %inhibition of cell growth was determined, as scaled to wells containing zero cells (100% inhibition) and wells containing cells not exposed to any drug (100% growth). Inhibition was only minimally additive for Co-F-1236 cells, while combination treatment actively reduced inhibition rate in Co-O-172 cells. (I) As (H), except the data for each bar is scaled to wells containing dabrafenib alone (100% growth for that condition) to examine the effects of trametinib alone. Here, as the concentration of dabrafenib is increased, the effect due to trametinib appears to decrease.
